Extending the resistance axis, proteomic studies identify glyoxalase 1 (Glo1) overexpression as a key contributor to multidrug resistance in breast cancer by detoxifying methylglyoxal and suppressing apoptosis. The gene discussed is GLO1; the disease is breast carcinoma.